Homogenous subgroups of atypical meningiomas defined using oncogenic signatures: basis for a new grading system?
Meningiomas are the most common brain tumor with a prevalence of 3% in the population. Histological grading of meningiomas (1 through 3) has a major role in determining treatment choice and predicting outcome. While largely indolent grade 1 and the highly aggressive grade 3 meningiomas as considered mostly homogenous in clinical behavior, atypical or grade 2 meningiomas have highly diverse biological properties. Our aim was to identify homogenous subgroups of atypical meningiomas with the working hypothesis that these subgroups would share features with grade 1 and grade 3 counterparts. We carried out systems level analysis by gene module discovery using co-expression networks on the transcriptomics of 212 meningiomas. The newly identified subgroups were characterized in terms of recurrence rate and overlapping biological processes in gene ontology. We were able to reclassify 33 of 46 atypical meningiomas (72%) into a benign \"grade 1-like\" (14/46) and malignant \"grade 3-like\" (19/46) subgroup based on oncogenic signatures. Recurrence rates of \"Grade 1-like\" and \"grade 3-like\" tumors was 0% and 72% respectively. These two new subgroups showed similar recurrence rates and concordant biological processes with the respected grades. Our findings help resolve the heterogeneity/uncertainty around atypical meningioma biology and identify subgroups more homogenous than in prior studies. These results may help reshape prediction, follow-up planning, treatment decisions and recruitment protocols for future and ongoing clinical trials. The findings demonstrate the conceptual advantage of systems biology approaches and underpin the utility of molecular signatures as complements to the current histological grading system.